LATEST NEWS
Pharma Integrates 2020 – Connect with pharma leaders pioneering change
Click here for Track 1, Click here for Track 2, Click here for Track 3, Click here for Track 4
Bio Integrates 2020 – Engage with the community transforming the biotech sector
Click here for Track 1, Click here for Track 2, Click here for Track 3
MedTech Integrates 2020
All sessions now available on-demand!
Click here for Track 1, Click here for Track 2, Click here for Track 3
Quotient Sciences CEO talks acquisitions, efficiency and finding cures fast
Mark Egerton, Chief Executive Officer, Quotient Sciences, spoke to Lu Rahman about the company’s acquisition of Arcinova and what it means for the drug discovery sector.
Additional Positive Interim Results from Nanoform’s Clinical Study
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
CatSci further strengthens its material science, analytical science and preformulation capabilities with a £3 million investment
CatSci, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, is expanding its capabilities in material science, analytical science and preformulation studies to better serve its customers’ needs.
MOST POPULAR READS
LIFE SCIENCE INTEGRATES INDUSTRY INSIGHTS
Treatment
READ MORE | 5 Minute Read
Technology
READ MORE | 7 minute read
Talent
READ MORE | 5 Minute Read
Tactics
READ MORE | 5 Minute Read
Considering The Patient
READ MORE | 5 Minute Read
Catapults
READ MORE | 5 Minute Read
MARCO MOHWINCKEL INSIGHTS
Marco Mohwinckel: Revolutionising Drug Discover With Big Data And AI
READ MORE | 10 Minute Read
Marco Mohwinckel:
Backend and Buzzing:
Blockchain
READ MORE | 20 Minute Read
Marco Mohwinckel:
The Disruptive Power
of Pharma AI
READ MORE | 10 Minute Read
VISIT OUR INSIGHTS AREAS
WHITE PAPERS
EFFECTIVE AND FAST APPROVAL OF INCIDENT INVESTIGATION REPORTS
Deviations, incidents or investigations – whatever you call them – require an efficient and effective system for review and approval.
DRUG SHORTAGES WHY DO THEY HAPPEN AND HOW CAN WE STOP THEM?
With 56% of U.S. health care providers reporting to have changed patient care or delayed therapy as a result of drug shortages, John Johnson looks at the key reasons behind the issue and what you can do to stop it.
MANAGING A QUALITY SYSTEM WITH A 50% STAFF REDUCTION
Imagine you are the Quality Director of a site manufacturing critical medicinal products or medical devices. You have a sickness absence rate of 50% of QA and QC staff. What do you do?
LATEST NEWS
Quotient Sciences CEO talks acquisitions, efficiency and finding cures fast
Mark Egerton, Chief Executive Officer, Quotient Sciences, spoke to Lu Rahman about the company’s acquisition of Arcinova and what it means for the drug discovery sector.
Additional Positive Interim Results from Nanoform’s Clinical Study
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
CatSci further strengthens its material science, analytical science and preformulation capabilities with a £3 million investment
CatSci, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, is expanding its capabilities in material science, analytical science and preformulation studies to better serve its customers’ needs.
INDUSTRY INSIGHTS
Treatment
A key part of Pharma Integrates’ agenda revolved around the efficacy of different types of treatment, how to get therapies to patients quickly and effectively, the impact of personalised medicine, technological advances in drug discovery and tackling rare diseases.
Technology
With investment in the digital health sector reaching a record $8.1bn (£6.2bn) in 2018 and with one third of all US healthcare investment now in digital health technology, it is becoming increasingly important that the life sciences sector keeps up to date with the latest technological advances.
Talent
A company’s staff is its greatest asset, but with every business struggling to recruit and retain key talent, and with the very real threat of a Brexit “brain drain”, how can the life sciences industry attract the best and brightest?
Tactics
In an ever-changing pharmaceutical industry, both in terms of innovation and R&D, as well as from a business and funding perspective, the subject of strategic development and tactics to boost productivity was firmly on the agenda at November’s Pharma Integrates.
ON TWITTER
WHITE PAPERS
EFFECTIVE AND FAST APPROVAL OF INCIDENT INVESTIGATION REPORTS
Deviations, incidents or investigations – whatever you call them – require an efficient and effective system for review and approval.
DRUG SHORTAGES WHY DO THEY HAPPEN AND HOW CAN WE STOP THEM?
With 56% of U.S. health care providers reporting to have changed patient care or delayed therapy as a result of drug shortages, John Johnson looks at the key reasons behind the issue and what you can do to stop it.
MANAGING A QUALITY SYSTEM WITH A 50% STAFF REDUCTION
Imagine you are the Quality Director of a site manufacturing critical medicinal products or medical devices. You have a sickness absence rate of 50% of QA and QC staff. What do you do?
LATEST NEWS
Quotient Sciences CEO talks acquisitions, efficiency and finding cures fast
Mark Egerton, Chief Executive Officer, Quotient Sciences, spoke to Lu Rahman about the company’s acquisition of Arcinova and what it means for the drug discovery sector.
Additional Positive Interim Results from Nanoform’s Clinical Study
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
CatSci further strengthens its material science, analytical science and preformulation capabilities with a £3 million investment
CatSci, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, is expanding its capabilities in material science, analytical science and preformulation studies to better serve its customers’ needs.
INDUSTRY INSIGHTS
Treatment
A key part of Pharma Integrates’ agenda revolved around the efficacy of different types of treatment, how to get therapies to patients quickly and effectively, the impact of personalised medicine, technological advances in drug discovery and tackling rare diseases.
Technology
With investment in the digital health sector reaching a record $8.1bn (£6.2bn) in 2018 and with one third of all US healthcare investment now in digital health technology, it is becoming increasingly important that the life sciences sector keeps up to date with the latest technological advances.
Talent
A company’s staff is its greatest asset, but with every business struggling to recruit and retain key talent, and with the very real threat of a Brexit “brain drain”, how can the life sciences industry attract the best and brightest?
Tactics
In an ever-changing pharmaceutical industry, both in terms of innovation and R&D, as well as from a business and funding perspective, the subject of strategic development and tactics to boost productivity was firmly on the agenda at November’s Pharma Integrates.
ON TWITTER
PREVIOUS EVENTS
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.